Amyloid Beta-peptide 1-40 and Alzheimer's Disease (ADAB40)

CHU de Reims

Status

Completed

Conditions

Alzheimer Disease

Treatments

Biological: spinal fluid collection

Study type

Interventional

Funder types

Other

Identifiers

NCT02770482

PA13050

Details and patient eligibility

About

The combined measurement of Ab42 and tau protein (total and phosphorylated) in the spinal fluid has been shown to be promising in the diagnosis of Alzheimer's disease (AD), and has justified its inclusion new diagnostic criteria. However, it can sometimes yield discordant results that are not discriminant (isolated variation in Ab42 or P-181 Tau). To answer this challenge, a new marker has been developed in recent years, namely amyloid beta-peptide 1-40 (Aβ40). This marker reflects the patient's total amyloid deposits and is used to calculate the Aβ42/Aβ40 ratio. This ratio measures the relative variation of Aβ42 as compared to the total amyloid burden. Literature data on this topic are sparse and to date, no report has been published evaluating the utility of this marker in the diagnostic strategy for AD.

Enrollment

204 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patients attending the Memory Clinic of Champagne-Ardennes for memory disorders, and
Whose diagnostic work-up requires assessment of biomarkers present in the cerebrospinal fluid are considered eligible for inclusion in this study.

Exclusion criteria